- +86-13363869198
- weimiaohb@126.com
Apr . 01, 2024 17:55 Back to list
Zayepro Pharmaceuticals Ltd about Sterile FillFinish Capabilities
Introduction
Zayepro Pharmaceuticals Ltd. is a contract development and manufacturing organization (CDMO) specializing in sterile fill-finish services for the pharmaceutical and biotechnology industries. Positioned within the biopharmaceutical supply chain as a crucial late-stage manufacturing partner, Zayepro offers aseptic filling of vials, syringes, and cartridges. Core performance characteristics center around maintaining stringent sterility assurance levels, precise fill volumes, and adherence to global regulatory guidelines. A primary pain point addressed is the increasing demand for flexible manufacturing capacity, particularly for clinical trial materials and small-to-mid-size commercial batches, alleviating pressure on internal manufacturing facilities and reducing time-to-market for novel therapies. Zayepro’s competency lies in handling diverse formulation types, including biologics, vaccines, and small molecules, requiring a deep understanding of process optimization and quality control.
Material Science & Manufacturing
The primary materials utilized in Zayepro’s operations encompass Type I borosilicate glass for vials and cartridges, Cyclic Olefin Polymer (COP) and Cyclic Olefin Copolymer (COC) for syringes, and high-density polyethylene (HDPE) or polypropylene (PP) for stoppers and closures. Borosilicate glass is selected for its low leachables, chemical inertness, and resistance to thermal shock. COP/COC offer excellent clarity, barrier properties against oxygen and moisture, and biocompatibility. Stopper materials are chosen based on compatibility with the drug product and maintainability of hermetic seals. Manufacturing processes are heavily governed by aseptic principles. Vial/cartridge washing involves multiple water-for-injection (WFI) rinses followed by depyrogenation through heat sterilization (typically 250°C for 30 minutes). Syringe assembly occurs in ISO Class 5 cleanrooms, requiring precise robotic manipulation and visual inspection. Filling operations employ Restricted Access Barrier Systems (RABS) or isolators to minimize human intervention. Critical parameters include filling speed, needle gauge, and stopper insertion force, all monitored and controlled within pre-defined specifications. Lyophilization (freeze-drying), if required, involves controlled freezing, primary drying (sublimation of water), and secondary drying (removal of bound water) under vacuum, requiring careful temperature and pressure profiling to maintain product stability. Material compatibility studies, including extractables and leachables testing, are essential to ensure no adverse interactions between the container closure system and the drug product.
Performance & Engineering
Performance analysis within Zayepro's operations centers on sterility assurance, container closure integrity (CCI), and fill accuracy. Sterility is validated through comprehensive environmental monitoring, bioburden testing, and terminal sterilization validation (where applicable). CCI is assessed through helium leak testing, dye ingress testing, and high-voltage leak testing, ensuring the container maintains a hermetic seal throughout the product’s shelf life. Fill accuracy is determined through gravimetric analysis and automated fill weight monitoring. Engineering controls include HVAC systems with HEPA filtration maintaining positive pressure differentials, validated cleaning procedures, and robust equipment qualification (IQ/OQ/PQ). Environmental resistance testing evaluates the impact of temperature, humidity, and light exposure on product stability. Compliance requirements are dictated by regulatory agencies such as the FDA (US), EMA (Europe), and PMDA (Japan), demanding adherence to cGMP (current Good Manufacturing Practice) guidelines. Force analysis is crucial in stopper insertion, ensuring proper sealing without damaging the glass or causing micro-cracks. Statistical Process Control (SPC) is implemented across all critical process parameters to monitor trends and prevent deviations. Detailed risk assessments (FMEA) are conducted to identify potential failure points and implement mitigating controls.
Technical Specifications
| Parameter | Vial Filling (2R) | Syringe Filling (1R) | Cartridge Filling (1R) |
|---|---|---|---|
| Fill Volume Range (mL) | 0.2 – 10 | 0.1 – 5 | 0.5 – 3 |
| Fill Accuracy (% CV) | ≤ 1.0% | ≤ 1.5% | ≤ 1.2% |
| Sterility Assurance Level (SAL) | 10-6 | 10-6 | 10-6 |
| Container Closure Integrity (Leak Rate) | ≤ 1 x 10-5 cm3/sec (Helium) | ≤ 2 x 10-6 cm3/sec (Helium) | ≤ 1 x 10-5 cm3/sec (Helium) |
| Batch Size Range (Units) | 100 – 50,000 | 50 – 25,000 | 100 – 10,000 |
| Temperature Control Range (°C) | 2 – 8, -20 | 2 – 8, -80 | 2 – 8 |
Failure Mode & Maintenance
Potential failure modes in sterile fill-finish operations include particulate contamination, microbial contamination, stopper defects (cracking, misalignment), fill volume inaccuracies, and CCI failures. Particulate contamination can arise from equipment wear, environment, or lyophilization processes. Microbial contamination typically results from breaches in aseptic technique. Stopper defects are linked to material flaws, improper insertion, or incompatibility with the formulation. Fill volume inaccuracies stem from equipment malfunctions or process deviations. CCI failures are often caused by stopper damage, inadequate crimping, or material degradation. Maintenance strategies prioritize preventative maintenance (PM) on critical equipment, including autoclaves, filling machines, lyophilizers, and HVAC systems. PM schedules encompass lubrication, filter replacement, seal inspections, and calibration. Root cause analysis (RCA) is performed for all deviations, utilizing techniques like 5 Whys and Fishbone diagrams to identify contributing factors. Corrective and Preventative Actions (CAPA) are implemented to address the root causes and prevent recurrence. Regular equipment qualification (re-qualification) is performed to ensure continued compliance with cGMP requirements. Robust change control procedures are essential for any modifications to equipment, processes, or materials.
Industry FAQ
Q: What is your capacity for handling highly potent compounds?
A: Zayepro Pharmaceuticals has dedicated containment suites designed to safely handle highly potent APIs (HPAPIs). These suites incorporate enhanced engineering controls, including dedicated HVAC systems, negative pressure differentials, and specialized PPE protocols, adhering to Occupational Exposure Limit (OEL) guidelines and ensuring operator safety and product integrity.
Q: How do you ensure traceability of materials throughout the manufacturing process?
A: We utilize a comprehensive Electronic Batch Record (EBR) system integrated with 21 CFR Part 11 compliance. This system captures detailed information on all materials, equipment, and personnel involved in each batch, providing complete traceability from raw material receipt to finished product release. Serialization and barcode scanning are employed throughout the process.
Q: What is your experience with lyophilization cycle development?
A: Our formulation development team has extensive experience in lyophilization cycle development, employing Design of Experiments (DoE) methodologies to optimize freeze-drying parameters for product stability and reconstitution properties. We utilize specialized equipment for thermal analysis and resistance measurements to characterize product behavior during lyophilization.
Q: Can you accommodate different container types beyond vials and syringes?
A: While vials and syringes are our primary focus, we have the capability to handle other container types, including cartridges and prefilled pens, with appropriate validation and process adjustments. We assess each new container type for compatibility and manufacturability.
Q: How do you manage change control for client formulations?
A: We operate a robust change control system adhering to ICH Q7 guidelines. Any changes to client formulations require a formal change request, impact assessment, and approval by both Zayepro's quality team and the client. All changes are meticulously documented and validated before implementation.
Conclusion
Zayepro Pharmaceuticals Ltd. distinguishes itself as a reliable CDMO partner through its commitment to stringent quality control, aseptic manufacturing expertise, and adherence to global regulatory standards. The company’s core competency lies in providing flexible fill-finish solutions for a diverse range of pharmaceutical formulations, addressing a critical need for capacity and specialization within the biopharmaceutical industry. Maintaining sterility assurance, ensuring container closure integrity, and providing accurate fill volumes are paramount to Zayepro’s operational success.
Looking ahead, Zayepro continues to invest in advanced technologies, such as robotic automation and real-time release testing, to enhance efficiency and further reduce the risk of contamination. Continued emphasis on process analytical technology (PAT) and data analytics will enable proactive process monitoring and optimization, ensuring consistent product quality and client satisfaction. By fostering collaborative partnerships and prioritizing scientific rigor, Zayepro is positioned to remain a key player in the evolving landscape of pharmaceutical manufacturing.